Last Updated: 16/07/2025
Self-assembling protein nanoparticles (SAPN), containing PfCSP epitopes (FMP014) combined with (ALF with QS-21)
Objectives
The objective of this study is to measure the safety dosage and assess the expected immunological response associated with the candidate malaria vaccine FMP013/ALFQ.
United States Army Medical Research and Development Command (USAMRDC), United States
Walter Reed Army Institute of Research (WRAIR), United States
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability, and efficacy of Plasmodium falciparum Malaria Protein 014 (FMP014) combined with (ALF with QS-21), saponin molecule derived from the bark of Quillaja species (ALFQ) in healthy adult volunteers at different doses and dosing schedules.
Study type: Interventional
Enrollment: 46 participants
Primary purpose: Prevention
Allocation :Non-Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT04296279
Phase: Phase I
Mar 2020 — Dec 2023
Related Resources
